



We claim:

1. A compound of the general formula (I),



- 5 stereoisomers thereof and pharmaceutically acceptable salts thereof,  
wherein,

$R_1$  is alkyl or cycloalkyl;



$R_5$  is fluoro, hydroxy, alkoxy or ;

X is hydrogen, hydroxy or halogen;


"n" is an integer ranging from 0 to 1, both inclusive;

"m" is an integer ranging from 1 to 4, both inclusive;

"p" is an integer ranging from 0 to 3, both inclusive.





2. A compound selected from:

(a) a compound of formula (Ia):



or their stereoisomers and pharmaceutically acceptable salts thereof,  
wherein,

R<sub>1</sub> is alkyl or cycloalkyl;



R<sub>5</sub> is fluoro, hydroxy or alkoxy;


X is hydrogen, hydroxy or halogen;

"n" is an integer ranging from 0 to 1, both inclusive;

"m" is an integer ranging from 1 to 4, both inclusive;


"p" is an integer ranging from 0 to 3, both inclusive.

(b) a compound of formula (Ib):



or their stereoisomers and pharmaceutically acceptable salts thereof,  
 wherein,

$R_1$  is alkyl or cycloalkyl;




$R_2$  is

X is hydroxy;




"n" is an integer ranging from 0 to 1, both inclusive.

(c) a compound of formula (Ic):



or their stereoisomers and pharmaceutically acceptable salts thereof,  
 wherein,

$R_1$  is alkyl;




X is hydrogen or hydroxy;

"n" is an integer ranging from 0 to 1, both inclusive;




"p" is an integer ranging from 0 to 3, both inclusive.

(d) a compound of formula (Id):



or their stereoisomers and pharmaceutically acceptable salts thereof,  
wherein,

R<sub>1</sub> is alkyl;




R<sub>5</sub> is fluoro, hydroxy or alkoxy;

X is hydrogen, hydroxy or halogen;




"n" is an integer ranging from 0 to 1, both inclusive.

(e) a compound of formula (Ie):



or their stereoisomers and pharmaceutically acceptable salts thereof,  
wherein,

R<sub>1</sub> is alkyl;



R<sub>2</sub> is alkyl,

R<sub>5</sub> is alkoxy;

X is hydrogen;

"n" is an integer ranging from 0 to 1, both inclusive;

"p" is an integer ranging from 0 to 3, both inclusive.

3. The compound according to claims 1 and 2, which is selected from the group consisting of:  
N-[(N-tetrahydropyran-4-yl methyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-[(N-tetrahydropyran-4-yl methyl) piperidin-4-yl methyl]-2-ethyl-2H-indazole-7-carboxamide fumarate;

N-[N-(3-methoxy propyl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide oxalate;

N-[N-(3-methoxy propyl) piperidin-4-ylmethyl]-2-ethyl-2H-indazole-7-carboxamide fumarate;

- N-[N-(3-methoxy propyl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-ethyl-2H-indazole-7-carboxamide oxalate;
- N-[N-(3-hydroxy-2,2-dimethyl propyl) piperidin-4-ylmethyl]-2-isopropyl-2H-indazole-7-carboxamide L(+) Tartarate;
- 5 N-[N-(2-fluoroethyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;
- N-[N-benzyl morpholin-2-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;
- N-[(N-tetrahydropyran-4-yl methyl) morpholine-2-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;
- N-[N-(tetrahydropyran-4-yl methyl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;
- 10 N-[N-(1-hydroxy cyclopentylmethyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide L(+) tartarate;
- N-[N-(tetrahydropyran-4-yl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;
- 15 N-(N-isopropyl piperidin-4-ylmethyl)-2-isopropyl-2H-indazole-7-carboxamide fumarate;
- N-(N-cyclobutyl piperidin-4-yl methyl)-2-isopropyl-2H-indazole-7-carboxamide fumarate;
- N-(N-cyclohexyl piperidin-4-yl methyl)-2-isopropyl-2H-indazole-7-carboxamide fumarate;
- N-(N-isopropyl-3-aza bicyclo[3.1.0]hexane-6-yl methyl)-2-isopropyl-2H-indazole-7-carboxamide fumarate;
- 20 N-[N-(4-hydroxy tetrahydro pyran-4-yl methyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;
- N-[N-(tetrahydro pyran-4-yl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-ethyl-2H-indazole-7-carboxamide oxalate;
- N-(N-isopropyl piperidine-4-yl)-2-isopropyl-2H-indazole-7-carboxamide fumarate;
- 25 N-(N-cyclopropylmethyl piperidine-4-yl)-2-isopropyl-2H-indazole-7-carboxamide fumarate;
- N-(N-cyclobutylmethyl piperidine-4-yl)-2-isopropyl-2H-indazole-7-carboxamide fumarate;
- N-[(N-tetrahydropyran-4-yl methyl)-4-fluoro piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;
- N-[(N-tetrahydrofuran-3-yl methyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide
- 30 N-[N-(3-methoxy propyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;
- N-[N-(2-methoxy ethyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;
- 35 N-[(N-tetrahydropyran-4-yl methyl)-4-hydroxy piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;

- N-[(N-tetrahydropyran-4-yl)-4-hydroxy piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;
- N-[N-(3-methoxy propyl)-4-hydroxypiperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;
- 5 N-[N-(3-Hydroxy-3-methyl butyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;
- N-[N-(2-hydroxy-2-methyl propyl)-4-hydroxy piperidin-4-ylmethyl]-2-isopropyl-2H-indazole-7-carboxamide oxalate;
- N-[N-(4-hydroxy tetrahydropyran-4-yl methyl)-4-fluoro piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide L(+) Tartarate;
- 10 N-[N-(2-hydroxy-2-methyl propyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide L(+) Tartarate;
- N-[N-(2-Methoxy-2-methyl propyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;
- 15 N-[N-(2-fluoro-2-methyl propyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide L(+) Tartarate;
- N-[N-(2-hydroxy-2-methyl propyl)-4-fluoro piperidin-4-ylmethyl]-2-isopropyl-2H-indazole-7-carboxamide L(+) Tartarate;
- N-[N-(2-hydroxy-2-methyl propyl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide L(+) Tartarate;
- 20 2-Isopropyl-7-{5-[1-(3-methoxy propyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-2H-indazole fumarate;
- 2-Isopropyl-7-{5-[1-(tetrahydropyran-4-yl methyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-2H-indazole fumarate;
- 25 2-Isopropyl-7-{5-[1-(tetrahydropyran-4-yl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-2H-indazole fumarate;
- N-[N-(2-hydroxy-2-methyl propyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide Oxalate; and their stereoisomers and pharmaceutically acceptable salts.
- 30 4. A pharmaceutical composition comprising a compound according to any of claims 1 to 3 and pharmaceutically acceptable excipients.
5. The pharmaceutical composition according to claim 4, for the treatment of clinical conditions mediated through 5-HT<sub>4</sub> receptor agonists such as alzheimer's disease, schizpherenia, attention
- 35 deficit hyperactivity disorder, huntington's disease, parkinson's disease, depression or psychiatric disorders

6. A method of treating cognitive disorders, dementia, attention deficit hyperactivity disorder, schizophrenia and pain, comprising administering to a patient in need thereof an effective amount of a compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 3.

5


7. Use of a compound according to any one of the claims 1 to 3 in the manufacture of medicament for the treatment of diseases related to 5-HT<sub>4</sub> receptor agonists.

8. The use of compound according to the claim 7, for the treatment of clinical conditions such as Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder, huntington's disease, Parkinson's disease, depression or psychiatric disorders.

10






**We claim:**

1. A compound of the general formula (I),



or a stereoisomer, a pharmaceutically acceptable salt thereof,  
wherein,

$R_1$  is alkyl or cycloalkyl;



$R_5$  is fluoro, hydroxy, alkoxy or ;

$X$  is hydrogen, hydroxy or halogen;


" $n$ " is an integer ranging from 0 to 1, both inclusive;

"m" is an integer ranging from 1 to 4, both inclusive;

"p" is an integer ranging from 0 to 3, both inclusive.

2. The compound as claimed in claim 1, wherein the compound is selected from:






(a) a compound of formula (Ia):



or a stereoisomer, a pharmaceutically acceptable salt thereof,

wherein,

R<sub>1</sub> is alkyl or cycloalkyl;



R<sub>5</sub> is fluoro, hydroxy or alkoxy;


X is hydrogen, hydroxy or halogen;

"n" is an integer ranging from 0 to 1, both inclusive;

"m" is an integer ranging from 1 to 4, both inclusive;




"p" is an integer ranging from 0 to 3, both inclusive;

(b) a compound of formula (Ib):



or a stereoisomer, a pharmaceutically acceptable salt thereof,  
wherein,


R<sub>1</sub> is alkyl or cycloalkyl;



X is hydroxy;


"n" is an integer ranging from 0 to 1, both inclusive;

(c) a compound of formula (Ic):



or a stereoisomer, a pharmaceutically acceptable salt thereof,  
wherein,

R<sub>1</sub> is alkyl;




R<sub>5</sub> is alkoxy or  OH;

X is hydrogen or hydroxy;

"n" is an integer ranging from 0 to 1, both inclusive;



"p" is an integer ranging from 0 to 3, both inclusive;


(d) a compound of formula (Id):



or a stereoisomer, a pharmaceutically acceptable salt thereof,  
wherein,

R<sub>1</sub> is alkyl;






$R_5$  is fluoro, hydroxy or alkoxy;

$X$  is hydrogen, hydroxy or halogen;




" $n$ " is an integer ranging from 0 to 1, both inclusive;

(e) a compound of formula (Ie):



or a stereoisomer, a pharmaceutically acceptable salt thereof,  
wherein,

$R_1$  is alkyl;



$R_2$  is alkyl,

$R_5$  is alkoxy;

$X$  is hydrogen;

" $n$ " is an integer ranging from 0 to 1, both inclusive;

" $p$ " is an integer ranging from 0 to 3, both inclusive.

3. The compound according to claim 1, which is selected from the group consisting of:  
N-[N-(tetrahydropyran-4-yl methyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-[N-(tetrahydropyran-4-yl methyl) piperidin-4-yl methyl]-2-ethyl-2H-indazole-7-carboxamide fumarate;

N-[N-(3-methoxy propyl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide oxalate;

N-[N-(3-methoxy propyl) piperidin-4-ylmethyl]-2-ethyl-2H-indazole-7-carboxamide fumarate;

N-[N-(3-methoxy propyl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-ethyl-2H-indazole-7-carboxamide oxalate;

N-[N-(3-hydroxy-2,2-dimethyl propyl) piperidin-4-ylmethyl]-2-isopropyl-2H-indazole-7-carboxamide L(+) Tartarate;

N-[N-(2-fluoroethyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;

N-[N-benzyl morpholin-2-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-[N-(tetrahydropyran-4-yl methyl) morpholine-2-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;

N-[N-(tetrahydropyran-4-yl methyl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;

N-[N-(1-hydroxy cyclopentylmethyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide L(+) tartarate;

N-[N-(tetrahydropyran-4-yl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;

N-(N-isopropyl piperidin-4-ylmethyl)-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-(N-cyclobutyl piperidin-4-yl methyl)-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-(N-cyclohexyl piperidin-4-yl methyl)-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-(N-isopropyl-3-aza bicyclo[3.1.0]hexane-6-yl methyl)-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-[N-(4-hydroxy tetrahydro pyran-4-yl methyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-[N-(tetrahydro pyran-4-yl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-ethyl-2H-indazole-7-carboxamide oxalate;

N-(N-isopropyl piperidine-4-yl)-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-(N-cyclopropylmethyl piperidine-4-yl)-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-(N-cyclobutylmethyl piperidine-4-yl)-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-[N-(tetrahydropyran-4-yl methyl)-4-fluoro piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;

N-[N-(tetrahydrofuran-3-yl methyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;

N-[N-(3-methoxy propyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-[N-(2-methoxy ethyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-[N-(tetrahydropyran-4-yl methyl)-4-hydroxy piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-[N-(tetrahydropyran-4-yl)-4-hydroxy piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-[N-(3-methoxy propyl)-4-hydroxypiperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide fumarate;

N-[N-(3-Hydroxy-3-methyl butyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;

N-[N-(2-hydroxy-2-methyl propyl)-4-hydroxy piperidin-4-ylmethyl]-2-isopropyl-2H-indazole-7-carboxamide oxalate;

N-[N-(4-hydroxy tetrahydropyran-4-yl methyl)-4-fluoro piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide L(+) Tartarate;

N-[N-(2-hydroxy-2-methyl propyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide L(+) Tartarate;

N-[N-(2-Methoxy-2-methyl propyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;

N-[N-(2-fluoro-2-methyl propyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide L(+) Tartarate;

N-[N-(2-hydroxy-2-methyl propyl)-4-fluoro piperidin-4-ylmethyl]-2-isopropyl-2H-indazole-7-carboxamide L(+) Tartarate;

N-[N-(2-hydroxy-2-methyl propyl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide L(+) Tartarate;

2-Isopropyl-7-{5-[1-(3-methoxy propyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-2H-indazole fumarate;

2-Isopropyl-7-{5-[1-(tetrahydropyran-4-yl methyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-2H-indazole fumarate;

2-Isopropyl-7-{5-[1-(tetrahydropyran-4-yl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-2H-indazole fumarate;

N-[N-(2-hydroxy-2-methyl propyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide Oxalate;

N-[N-(tetrahydropyran-4-yl methyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;

N-[N-(tetrahydropyran-4-yl methyl) piperidin-4-yl methyl]-2-ethyl-2H-indazole-7-carboxamide;

N-[N-(3-methoxy propyl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;

N-[N-(3-methoxy propyl) piperidin-4-ylmethyl]-2-ethyl-2H-indazole-7-carboxamide;  
 N-[N-(3-methoxy propyl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-ethyl-2H-indazole-7-carboxamide;  
 N-[N-(3-hydroxy-2,2-dimethyl propyl) piperidin-4-ylmethyl]-2-isopropyl-2H-indazole-7-carboxamide;  
 N-[N-benzyl morpholin-2-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;  
 N-[N-(1-hydroxy cyclopentylmethyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;  
 N-(N-isopropyl piperidin-4-ylmethyl)-2-isopropyl-2H-indazole-7-carboxamide;  
 N-(N-cyclobutyl piperidin-4-yl methyl)-2-isopropyl-2H-indazole-7-carboxamide;  
 N-(N-cyclohexyl piperidin-4-yl methyl)-2-isopropyl-2H-indazole-7-carboxamide;  
 N-(N-isopropyl-3-aza bicyclo[3.1.0]hexane-6-yl methyl)-2-isopropyl-2H-indazole-7-carboxamide;  
 N-[N-(4-hydroxy tetrahydro pyran-4-yl methyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;  
 N-[N-(tetrahydro pyran-4-yl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-ethyl-2H-indazole-7-carboxamide;  
 N-(N-isopropyl piperidine-4-yl)-2-isopropyl-2H-indazole-7-carboxamide;  
 N-(N-cyclopropylmethyl piperidine-4-yl)-2-isopropyl-2H-indazole-7-carboxamide;  
 N-(N-cyclobutylmethyl piperidine-4-yl)-2-isopropyl-2H-indazole-7-carboxamide;  
 N-[N-(3-methoxy propyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;  
 N-[N-(2-methoxy ethyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;  
 N-[N-(tetrahydropyran-4-yl methyl)-4-hydroxy piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;  
 N-[N-(tetrahydropyran-4-yl)-4-hydroxy piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;  
 N-[N-(3-methoxy propyl)-4-hydroxypiperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;  
 N-[N-(2-hydroxy-2-methyl propyl)-4-hydroxy piperidin-4-ylmethyl]-2-isopropyl-2H-indazole-7-carboxamide;  
 N-[N-(4-hydroxy tetrahydropyran-4-yl methyl)-4-fluoro piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;  
 N-[N-(2-hydroxy-2-methyl propyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;  
 N-[N-(2-fluoro-2-methyl propyl) piperidin-4-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;  
 N-[N-(2-hydroxy-2-methyl propyl)-4-fluoro piperidin-4-ylmethyl]-2-isopropyl-2H-indazole-7-carboxamide;

N-[N-(2-hydroxy-2-methyl propyl)-3-aza bicyclo[3.1.0]hexane-6-yl methyl]-2-isopropyl-2H-indazole-7-carboxamide;

2-Isopropyl-7-{5-[1-(3-methoxy propyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-2H-indazole;

2-Isopropyl-7-{5-[1-(tetrahydropyran-4-yl methyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-2H-indazole; and

2-Isopropyl-7-{5-[1-(tetrahydropyran-4-yl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-2H-indazole;

or a stereoisomer, a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising a compound according to any one of the claims 1 to 3 and pharmaceutically acceptable excipients.

5. The pharmaceutical composition according to claim 4, for use in the treatment of clinical conditions mediated through 5-HT<sub>4</sub> receptor agonists selected from Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder, Huntington's disease, Parkinson's disease, depression or psychiatric disorders.

6. Use of the pharmaceutical composition according to claim 4 in the manufacture of medicament for the treatment of clinical conditions mediated through 5-HT<sub>4</sub> receptor agonists selected from Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder, Huntington's disease, Parkinson's disease, depression or psychiatric disorders.

7. The compound according to any one of the claims 1 to 3, for use in the treatment of cognitive disorders, dementia, attention deficit hyperactivity disorder, schizophrenia and pain.

8. Use of a compound according to any one of the claims 1 to 3 in the manufacture of medicament for the treatment of diseases related to 5-HT<sub>4</sub> receptor agonists.

9. The use of the compound according to the claim 8, wherein the diseases related to 5-HT<sub>4</sub> receptor agonists are selected from Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder, Huntington's disease, Parkinson's disease, depression or psychiatric disorders.